Impact of Nirsevimab on RSV and Non‐RSV Severe Respiratory Infections in Hospitalized Infants

20254 citationsJournal Articlegold Open Access

Authors

María Luz García‐García · Instituto de Salud Carlos III

Patricia Alonso‐López · Hospital Universitario Puerta de Hierro Majadahonda

Sonia Alcolea · Hospital Universitario Severo Ochoa

María Arroyas · Hospital Universitario Severo Ochoa

Francisco Pozo · Instituto de Salud Carlos III

Inmaculada Casas · Instituto de Salud Carlos III

María Iglesias‐Caballero

Abstract

Nirsevimab introduction was significantly associated with reduced hospitalizations and severity of RSV and other respiratory infections. Its use was associated with fewer admissions and reduced need for intensive care, especially in RSV-infected infants but also in HMPV and adenovirus-infected infants.

Topics & Keywords

Respiratory viral infections research Pneumonia and Respiratory Infections Neonatal Respiratory Health Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Influenza and Other Respiratory Viruses

Volume 19, Issue 5, pp. e70105-e70105

DOI: 10.1111/irv.70105

Field-Weighted Citation Impact: 5.68